{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T14:17:47Z","timestamp":1776262667843,"version":"3.50.1"},"reference-count":78,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Belinostat (PXD101), a hydroxamate\u2010class histone deacetylase inhibitor (HDACi), was approved by the US FDA for patients with relapsed or refractory peripheral T\u2010cell lymphoma (PTCL). This review covers belinostat's pharmacological characteristics (including its mode of action), pharmacokinetics, toxicity, drug interactions, and analytical methods. Belinostat inhibits HDACs from Classes I and II, which then raises the acetylation of both histone and nonhistone proteins, resulting in growth cycle arrest and ultimately leading to the death of the malignant cells. The pharmacokinetics of belinostat include a brief elimination half\u2010life and substantial first\u2010pass metabolism in the liver, mostly via UGT1A1. Belinostat's efficacy has been proven in numerous clinical trials, which also revealed a certain level of cytotoxicity specific to tumor cells. Belinostat and its potential metabolites have often been qualitatively and quantitatively estimated and tracked using several analytical methods including UPLC\u2010MS\/MS, HPLC\u2010UV, FTIR, TLC, NMR, and ESI\u2010MS. In terms of therapeutic use of belinostat, this review demonstrates how important it is to understand the metabolism and degradation pathways of belinostat, as well as possible drug\u2013drug interactions.<\/jats:p>","DOI":"10.1002\/bmc.70424","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:19:50Z","timestamp":1774430390000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tracing the Analytical Footprint of Belinostat: Exploring Pharmacology and Synthetic Framework"],"prefix":"10.1002","volume":"40","author":[{"given":"Sanket","family":"Chaudhari","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Quality Assurance School of Pharmacy &amp; Technology Management, SVKMs NMIMS  Shirpur Maharashtra India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3571-7859","authenticated-orcid":false,"given":"Hemant\u00a0Kumar","family":"Tatapudi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Quality Assurance School of Pharmacy &amp; Technology Management, SVKMs NMIMS  Shirpur Maharashtra India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jami","family":"Durgaganesh","sequence":"additional","affiliation":[{"name":"Stira Pharma  Fairfield New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishore\u00a0Raju","family":"Vatsavai","sequence":"additional","affiliation":[{"name":"Veranova LP  Devens MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saisneha","family":"Kandhagatla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Analysis and Quality Assurance Teegala Ram Reddy College of Pharmacy  Hyderabad India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/antiox9070599"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2013\u20101172"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23144"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201008\u20104143"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.oprd.6b00170"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M600007\u2010MCP200"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.04.004"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479\u20105876\u20105\u201049"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2012.01.008"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092558"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.212035"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541\u20107786.MCR\u201007\u20100324"},{"key":"e_1_2_11_15_1","unstructured":"Drug Bank. n.d. \u201cBelinostat (DB05015)\u2013DrugBank Database.\u201d"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.MCT\u201005\u20100285"},{"key":"e_1_2_11_17_1","unstructured":"FDA. n.d. \u201cHighlights of Prescribing Information.\u201dwww.fda.gov\/medwatch."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201005\u2010231548"},{"issue":"17","key":"e_1_2_11_19_1","first-page":"4916","article-title":"FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases","volume":"62","author":"Furumai R.","year":"2002","journal-title":"Cancer Research"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.4467"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2005.09.010"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.625"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.5530\/ijper.56.1s.43"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117218"},{"key":"e_1_2_11_25_1","unstructured":"1996. \u201cInternational Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Ich Harmonised Tripartite Guideline Stability Testing: Photostability Testing of New Drug Substances and Products Q1b Current Step 4 Version.\u201d"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.4155\/cli.13.53"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2014.50.5.2138703"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070779"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2012\u2010759"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.03.025"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.11.091"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.26452\/ijrps.v10i2.263"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20103119"},{"key":"e_1_2_11_35_1","first-page":"462","article-title":"Histone Deacetylase Inhibitors in the Treatment of Lymphoma","volume":"10","author":"Lemoine M.","year":"2010","journal-title":"Medical Oncology"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026831"},{"key":"e_1_2_11_37_1","first-page":"249","article-title":"The Effects of PXD101 on Proliferation and Apoptosis of Human Breast Cell Line MCF\u20107 and Its Mechanism","volume":"39","author":"Li Y.","year":"2012","journal-title":"Chinese Journal of Clinical Oncology"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15772"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.3.6.927"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637\u2010009\u20109219\u20107"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/11315680\u2010000000000\u201000000"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.02.047"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22185"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100463.2008.00957.x"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826076.2021.1906271"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010010\u20101495\u20106"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1039\/d2ra01969h"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20102020"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010015\u20102543\u20104"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102010\u201010\u2010312603"},{"issue":"8","key":"e_1_2_11_52_1","first-page":"721","article-title":"Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101","volume":"2","author":"Plumb J. A.","year":"2003","journal-title":"Molecular Cancer Therapeutics"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0275-8"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23243"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318191520c"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.12.1364"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2007.01.001"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058818"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201007\u20101786"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010010\u20101419\u20105"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010013\u20102132\u2010y"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010643569"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20100968"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.105.007369"},{"key":"e_1_2_11_66_1","unstructured":"US Food and Drug Administration. n.d. \u201cCenter for Drug Evaluation and Research.\u201d Application Number: 206256orig1s000. Clinical Pharmacology and Biopharmaceutics Review(s)."},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.13040\/ijpsr.0975\u20108232.7(11).4358\u201066"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2013.05.090"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15017"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.07.015"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2020.12.001"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010007\u20100622\u20105"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI69738"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.2395"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1930"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0021\u20109258(17)44885\u2010x"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph12040180"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31802c573e"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010016\u20100267\u20100"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70424","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bmc.70424","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.70424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T13:32:29Z","timestamp":1776259949000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.70424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/bmc.70424"],"URL":"https:\/\/doi.org\/10.1002\/bmc.70424","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"value":"0269-3879","type":"print"},{"value":"1099-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"2025-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70424"}}